Alpha Tau Medical Ltd.

NasdaqCM DRTS

Alpha Tau Medical Ltd. EPS (Diluted) for the year ending December 31, 2023: USD -0.42

Alpha Tau Medical Ltd. EPS (Diluted) is USD -0.42 for the year ending December 31, 2023, a 20.75% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Alpha Tau Medical Ltd. EPS (Diluted) for the year ending December 31, 2022 was USD -0.53, a 20.90% change year over year.
Alpha Tau Medical Ltd. EPS (Diluted) for the year ending December 31, 2021 was USD -0.67, a -204.55% change year over year.
Alpha Tau Medical Ltd. EPS (Diluted) for the year ending December 31, 2020 was USD -0.22, a -69.23% change year over year.
Alpha Tau Medical Ltd. EPS (Diluted) for the year ending December 31, 2019 was USD -0.13.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqCM: DRTS

Alpha Tau Medical Ltd.

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street
Employees	121
Sector	Health Care
Industries Clinical Trials Biotechnology Pharmaceuticals

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends

Past 5 years